While later stage tumors had a greater frequency of BRAF p.V600E mutations than stage 1 tumors did, the association between BRAF p.V600E mutations and survival persisted with stage adjustment and was evident across case groups defined by tumor site and sex. This evidence concerns the gene BRAF and neoplasm.